Geron (NASDAQ:GERN) Cut to Neutral at HC Wainwright

HC Wainwright cut shares of Geron (NASDAQ:GERN) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, Marketbeat.com reports. HC Wainwright also issued estimates for Geron’s FY2029 earnings at $0.60 EPS.

GERN has been the subject of a number of other reports. Barclays raised Geron to a “strong-buy” rating in a research note on Friday, November 29th. Needham & Company LLC raised their price target on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, B. Riley decreased their price target on Geron from $5.50 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Price Performance

Shares of Geron stock opened at $1.76 on Wednesday. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -5.50 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The stock has a 50 day moving average price of $2.97 and a 200-day moving average price of $3.80. Geron has a one year low of $1.46 and a one year high of $5.34.

Geron (NASDAQ:GERN) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million during the quarter, compared to analysts’ expectations of $45.29 million. Equities analysts expect that Geron will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Geron

Institutional investors and hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in Geron during the 4th quarter valued at $28,000. Integrated Wealth Concepts LLC purchased a new position in shares of Geron in the 4th quarter valued at $36,000. GF Fund Management CO. LTD. purchased a new position in shares of Geron in the 4th quarter valued at $45,000. Fifth Lane Capital LP purchased a new position in shares of Geron in the 4th quarter valued at $53,000. Finally, Readystate Asset Management LP purchased a new position in shares of Geron in the 3rd quarter valued at $58,000. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.